today announced that the company will present three posters for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2025 International Conference, which is scheduled to ...

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter ...

today announced that the company will present three posters for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society (ATS) 2025 International Conference, which is ...

This may be accompanied by slight sensory loss, difficulty passing urine, or fluctuating blood pressure. Weakness in facial muscles can cause drooling, further signalling the onset of this serious ...

Morningstar brands and products Company Portfolio ...

Static stretching and muscle growth caused a stir in bodybuilding circles last year when a study compared a stretching protocol to resistance training, and found those in the stretching group ...